Tissue-resident memory T cells in the era of (Neo) adjuvant melanoma management
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Tissue-resident memory T cells in the era of (Neo) adjuvant melanoma management
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 13, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2022-11-16
DOI
10.3389/fimmu.2022.1048758
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma
- (2022) Hussein A. Tawbi et al. NEW ENGLAND JOURNAL OF MEDICINE
- An activation to memory differentiation trajectory of tumor-infiltrating lymphocytes informs metastatic melanoma outcomes
- (2022) Abhinav Jaiswal et al. CANCER CELL
- Hobit and Blimp‐1 regulate T RM abundance after LCMV infection by suppressing tissue exit pathways of T RM precursors
- (2022) Loreto Parga‐Vidal et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial
- (2022) Jason J Luke et al. LANCET
- LAG3 associates with TCR–CD3 complexes and suppresses signaling by driving co-receptor–Lck dissociation
- (2022) Clifford Guy et al. NATURE IMMUNOLOGY
- Central memory T cells are the most effective precursors of resident memory T cells in human skin
- (2022) Tiago R. Matos et al. Science Immunology
- Tissue-resident memory and circulating T cells are early responders to pre-surgical cancer immunotherapy
- (2022) Adrienne M. Luoma et al. CELL
- NeoTrio: Randomized trial of neoadjuvant (NAT) pembrolizumab (Pembro) alone, in sequence (SEQ) with, or concurrent (CON) with dabrafenib plus trametinib (D+T) in resectable BRAF-mutant stage III melanoma to determine optimal combination of therapy.
- (2022) Georgina V. Long et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab (NIVO) + relatlimab (RELA) versus NIVO in previously untreated metastatic or unresectable melanoma: OS and ORR by key subgroups from RELATIVITY-047.
- (2022) Hussein A. Tawbi et al. JOURNAL OF CLINICAL ONCOLOGY
- Distant metastasis-free survival with pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: The phase 3 KEYNOTE-716 study.
- (2022) Georgina V. Long et al. JOURNAL OF CLINICAL ONCOLOGY
- Tissue-resident memory CD8+ T cells possess unique transcriptional, epigenetic and functional adaptations to different tissue environments
- (2022) John T. Crowl et al. NATURE IMMUNOLOGY
- Runx3 drives a CD8+ T cell tissue residency program that is absent in CD4+ T cells
- (2022) Raíssa Fonseca et al. NATURE IMMUNOLOGY
- Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial
- (2022) Irene L. M. Reijers et al. NATURE MEDICINE
- Detailed spatial immunophenotyping of primary melanomas reveals immune cell subpopulations associated with patient outcome
- (2022) Grace H. Attrill et al. Frontiers in Immunology
- Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy
- (2022) Grace Heloise Attrill et al. Journal for ImmunoTherapy of Cancer
- Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)
- (2022) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- CD8+CD103+ tissue-resident memory T cells convey reduced protective immunity in cutaneous squamous cell carcinoma
- (2021) Chester Lai et al. Journal for ImmunoTherapy of Cancer
- Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)
- (2021) Alexander M. Menzies et al. NATURE MEDICINE
- Intratumoral CD103+ CD8+ T cells predict response to PD-L1 blockade
- (2021) Romain Banchereau et al. Journal for ImmunoTherapy of Cancer
- Discrete tissue microenvironments instruct diversity in resident memory T cell function and plasticity
- (2021) Susan N. Christo et al. NATURE IMMUNOLOGY
- Hypoxia acts as an environmental cue for the human tissue-resident memory T cell differentiation program
- (2021) Farah Hasan et al. JCI Insight
- Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
- (2021) Jedd D. Wolchok et al. JOURNAL OF CLINICAL ONCOLOGY
- Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES)
- (2021) Peter Kar Han Lau et al. Journal for ImmunoTherapy of Cancer
- Enhancing Adoptive Cell Transfer with Combination BRAF-MEK and CDK4/6 Inhibitors in Melanoma
- (2021) Peter Kar Han Lau et al. Cancers
- Fatty acid oxidation controls CD8+ tissue-resident memory T cell survival in gastric adenocarcinoma
- (2020) Run Lin et al. Cancer Immunology Research
- TRM integrins CD103 and CD49a differentially support adherence and motility after resolution of influenza virus infection
- (2020) Emma C. Reilly et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition
- (2020) Jenny H. Lee et al. Nature Communications
- Multimodal Analysis of Composition and Spatial Architecture in Human Squamous Cell Carcinoma
- (2020) Andrew L. Ji et al. CELL
- Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial
- (2020) Paolo A Ascierto et al. LANCET ONCOLOGY
- Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma
- (2020) Reinhard Dummer et al. NEW ENGLAND JOURNAL OF MEDICINE
- CD49a Regulates Cutaneous Resident Memory CD8+ T Cell Persistence and Response
- (2020) Shannon K. Bromley et al. Cell Reports
- LAG-3: from molecular functions to clinical applications
- (2020) Takumi Maruhashi et al. Journal for ImmunoTherapy of Cancer
- Tumor Immunotherapy Using A2A Adenosine Receptor Antagonists
- (2020) Jinfeng Zhang et al. Pharmaceuticals
- Prevalence and Cellular Distribution of Novel Immune Checkpoint Targets Across Longitudinal Specimens in Treatment-naïve Melanoma Patients: Implications for Clinical Trials
- (2019) Jarem Edwards et al. CLINICAL CANCER RESEARCH
- Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy
- (2019) Tuba N. Gide et al. CANCER CELL
- Prognostic value of tumor-infiltrating lymphocytes in melanoma: a systematic review and meta-analysis
- (2019) Qiaofen Fu et al. OncoImmunology
- Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial
- (2019) Elisa A Rozeman et al. LANCET ONCOLOGY
- Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
- (2019) Caroline Robert et al. LANCET ONCOLOGY
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2019) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tissue-Resident Memory T Cells in Cancer Immunosurveillance
- (2019) Simone L. Park et al. TRENDS IN IMMUNOLOGY
- Tissue-resident memory CD8+ T cells amplify anti-tumor immunity by triggering antigen spreading through dendritic cells
- (2019) Evelyn Menares et al. Nature Communications
- CD103+Tumor-Resident CD8+T Cells Are Associated with Improved Survival in Immunotherapy-Naïve Melanoma Patients and Expand Significantly During Anti–PD-1 Treatment
- (2018) Jarem Edwards et al. CLINICAL CANCER RESEARCH
- Transcriptional programming of tissue-resident memory CD8 + T cells
- (2018) J Justin Milner et al. CURRENT OPINION IN IMMUNOLOGY
- Understanding Subset Diversity in T Cell Memory
- (2018) Stephen C. Jameson et al. IMMUNITY
- Tissue-resident memory T cells in tissue homeostasis, persistent infection, and cancer surveillance
- (2018) Thomas Gebhardt et al. IMMUNOLOGICAL REVIEWS
- Vitiligo Skin Is Imprinted with Resident Memory CD8 T Cells Expressing CXCR3
- (2018) Katia Boniface et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF -mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
- (2018) Reinhard Dummer et al. LANCET ONCOLOGY
- Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis
- (2018) Peter Savas et al. NATURE MEDICINE
- PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma
- (2018) Michael R. Migden et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
- (2018) Alexander M.M. Eggermont et al. NEW ENGLAND JOURNAL OF MEDICINE
- Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors
- (2018) Thomas Duhen et al. Nature Communications
- Vaccination-induced skin-resident memory CD8+ T cells mediate strong protection against cutaneous melanoma
- (2018) Felipe Gálvez-Cancino et al. OncoImmunology
- Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates
- (2018) Yannick Simoni et al. NATURE
- Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3
- (2018) Jun Wang et al. CELL
- Targeting Adenosine Receptor Signaling in Cancer Immunotherapy
- (2018) Kevin Sek et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Resident memory and recirculating memory T cells cooperate to maintain disease in a mouse model of vitiligo
- (2018) Jillian M. Richmond et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Tissue-resident memory CD8+ T cells promote melanoma–immune equilibrium in skin
- (2018) Simone L. Park et al. NATURE
- CD49a Expression Defines Tissue-Resident CD8 + T Cells Poised for Cytotoxic Function in Human Skin
- (2017) Stanley Cheuk et al. IMMUNITY
- Genomic analysis of melanoma evolution following a 30-year disease-free interval
- (2017) Jerry J. Miller et al. JOURNAL OF CUTANEOUS PATHOLOGY
- Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial
- (2017) Paolo A Ascierto et al. LANCET ONCOLOGY
- Whole-genome landscapes of major melanoma subtypes
- (2017) Nicholas K. Hayward et al. NATURE
- Elements of cancer immunity and the cancer–immune set point
- (2017) Daniel S. Chen et al. NATURE
- Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
- (2017) Jeffrey Weber et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
- (2017) Georgina V. Long et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
- (2016) Willy Hugo et al. CELL
- CD103 defines intraepithelial CD8+ PD1+ tumour-infiltrating lymphocytes of prognostic significance in endometrial adenocarcinoma
- (2016) Hagma H. Workel et al. EUROPEAN JOURNAL OF CANCER
- ABC transporters and NR4A1 identify a quiescent subset of tissue-resident memory T cells
- (2016) Chandra Sekhar Boddupalli et al. JOURNAL OF CLINICAL INVESTIGATION
- Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: A multi-institutional retrospective study
- (2016) Yasuhiro Nakamura et al. JOURNAL OF DERMATOLOGY
- Programs for the persistence, vigilance and control of human CD8+ lung-resident memory T cells
- (2016) Pleun Hombrink et al. NATURE IMMUNOLOGY
- PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma
- (2016) Paul T. Nghiem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
- (2016) Jesse M. Zaretsky et al. NEW ENGLAND JOURNAL OF MEDICINE
- The molecular profile of metastatic melanoma in Australia
- (2016) Megan Lyle et al. PATHOLOGY
- T cell-intrinsic S1PR1 regulates endogenous effector T-cell egress dynamics from lymph nodes during infection
- (2016) Alexandre P. Benechet et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Hobit and Blimp1 instruct a universal transcriptional program of tissue residency in lymphocytes
- (2016) L. K. Mackay et al. SCIENCE
- Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
- (2016) Daniel Sanghoon Shin et al. Cancer Discovery
- CD103+ intraepithelial T cells in high-grade serous ovarian cancer are phenotypically diverse TCRαβ+ CD8αβ+ T cells that can be targeted for cancer immunotherapy
- (2016) Fenne L. Komdeur et al. Oncotarget
- Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab
- (2016) Camille Hua et al. JAMA Dermatology
- PD-1 Blockade Expands Intratumoral Memory T Cells
- (2016) A. Ribas et al. Cancer Immunology Research
- Very Late Antigen-1 Marks Functional Tumor-Resident CD8 T Cells and Correlates with Survival of Melanoma Patients
- (2016) Timothy Murray et al. Frontiers in Immunology
- T-box Transcription Factors Combine with the Cytokines TGF-β and IL-15 to Control Tissue-Resident Memory T Cell Fate
- (2015) Laura K. Mackay et al. IMMUNITY
- Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
- (2015) Dirk Schadendorf et al. JOURNAL OF CLINICAL ONCOLOGY
- CD8+CD103+Tumor–Infiltrating Lymphocytes Are Tumor-Specific Tissue-Resident Memory T Cells and a Prognostic Factor for Survival in Lung Cancer Patients
- (2015) Fayçal Djenidi et al. JOURNAL OF IMMUNOLOGY
- Cutting Edge: CD69 Interference with Sphingosine-1-Phosphate Receptor Function Regulates Peripheral T Cell Retention
- (2015) Laura K. Mackay et al. JOURNAL OF IMMUNOLOGY
- Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
- (2015) Alexander M M Eggermont et al. LANCET ONCOLOGY
- Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
- (2015) Stefani Spranger et al. NATURE
- Proinflammatory microenvironments within the intestine regulate the differentiation of tissue-resident CD8+ T cells responding to infection
- (2015) Tessa Bergsbaken et al. NATURE IMMUNOLOGY
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Human skin is protected by four functionally and phenotypically discrete populations of resident and recirculating memory T cells
- (2015) Rei Watanabe et al. Science Translational Medicine
- T-cell exhaustion in the tumor microenvironment
- (2015) Y Jiang et al. Cell Death & Disease
- Galectin-3 Shapes Antitumor Immune Responses by Suppressing CD8+ T Cells via LAG-3 and Inhibiting Expansion of Plasmacytoid Dendritic Cells
- (2015) T. Kouo et al. Cancer Immunology Research
- Adenosine Receptor 2A Blockade Increases the Efficacy of Anti–PD-1 through Enhanced Antitumor T-cell Responses
- (2015) Paul A. Beavis et al. Cancer Immunology Research
- BRAFV600E Co-opts a Conserved MHC Class I Internalization Pathway to Diminish Antigen Presentation and CD8+ T-cell Recognition of Melanoma
- (2015) S. D. Bradley et al. Cancer Immunology Research
- Reflections on the Histopathology of Tumor-Infiltrating Lymphocytes in Melanoma and the Host Immune Response
- (2015) M. C. Mihm et al. Cancer Immunology Research
- Cutting Edge: Resident Memory CD8 T Cells Occupy Frontline Niches in Secondary Lymphoid Organs
- (2014) J. M. Schenkel et al. JOURNAL OF IMMUNOLOGY
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- (2014) Alexandra Snyder et al. NEW ENGLAND JOURNAL OF MEDICINE
- Persistence of skin-resident memory T cells within an epidermal niche
- (2014) A. Zaid et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Tumor-Infiltrating Lymphocytes Expressing the Tissue Resident Memory Marker CD103 Are Associated with Increased Survival in High-Grade Serous Ovarian Cancer
- (2013) J. R. Webb et al. CLINICAL CANCER RESEARCH
- BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma
- (2013) D. T. Frederick et al. CLINICAL CANCER RESEARCH
- The who's who of T-cell differentiation: Human memory T-cell subsets
- (2013) Yolanda D. Mahnke et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Skin-resident memory T cells keep herpes simplex virus at bay
- (2013) Thomas Gebhardt et al. IMMUNOLOGY AND CELL BIOLOGY
- Differential Localization of T-bet and Eomes in CD8 T Cell Memory Populations
- (2013) L. M. McLane et al. JOURNAL OF IMMUNOLOGY
- The developmental pathway for CD103+CD8+ tissue-resident memory T cells of skin
- (2013) Laura K Mackay et al. NATURE IMMUNOLOGY
- Blockade of A2Areceptors potently suppresses the metastasis of CD73+tumors
- (2013) Paul A. Beavis et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Tumor-Infiltrating Lymphocyte Grade Is an Independent Predictor of Sentinel Lymph Node Status and Survival in Patients With Cutaneous Melanoma
- (2012) Farhad Azimi et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-lived epithelial immunity by tissue-resident memory T (TRM) cells in the absence of persisting local antigen presentation
- (2012) L. K. Mackay et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma
- (2011) James S. Wilmott et al. CLINICAL CANCER RESEARCH
- Ultra-late recurrence of malignant melanoma after 40 years of quiescent disease
- (2011) D. Saleh et al. JOURNAL OF SURGICAL ONCOLOGY
- Targeting OX40 Promotes Lung-Resident Memory CD8 T Cell Populations That Protect against Respiratory Poxvirus Infection
- (2011) S. Salek-Ardakani et al. JOURNAL OF VIROLOGY
- A human memory T cell subset with stem cell–like properties
- (2011) Luca Gattinoni et al. NATURE MEDICINE
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Selective BRAFV600E Inhibition Enhances T-Cell Recognition of Melanoma without Affecting Lymphocyte Function
- (2010) A. Boni et al. CANCER RESEARCH
- Ultra-late recurrence of malignant melanoma after a disease-free interval of 41 years
- (2010) D. Terhorst et al. CLINICAL AND EXPERIMENTAL DERMATOLOGY
- PD-1/PD-L1 pathway and T-cell exhaustion in chronic hepatitis virus infection
- (2010) T. Watanabe et al. JOURNAL OF VIRAL HEPATITIS
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Macrophage Markers in Serum and Tumor Have Prognostic Impact in American Joint Committee on Cancer Stage I/II Melanoma
- (2009) Trine O. Jensen et al. JOURNAL OF CLINICAL ONCOLOGY
- Autoimmune Destruction of Skin Melanocytes by Perilesional T Cells from Vitiligo Patients
- (2009) Jasper G. van den Boorn et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Memory T cells in nonlymphoid tissue that provide enhanced local immunity during infection with herpes simplex virus
- (2009) Thomas Gebhardt et al. NATURE IMMUNOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started